GTx Inc. (GTXI)

Oncology Corporate Profile

Stock Performance

4.8500
0.0000

HQ Location

175 Toyota Plaza, 7th Floor
Memphis, TN 38103

Company Description

GTx is a biopharmaceutical company dedicated to the discovery, development, and commercialization of small molecules that selectively target hormone pathways to treat cancer, osteoporosis and bone loss, muscle wasting, and other serious medical conditions.

Website: http://www.gtxinc.com

Brand Generic Indication
Fareston??toremifene citrateFARESTON is indicated for the treatment of metastatic breast cancer in postmenopausal women with estrogen-receptor positive or unknown tumors.

View additional information on commercial products here »

  • Brand
  • Generic
  • Investigational
Brand / Product Class Area of Study Phase Partnership
Ostarine_ / enobosarm / GTx-024selective androgen receptor modulator (SARM)Cancer cachexia in Non Small Cell Lung Cancer (NSCLC) patientsIIIMerck
Capesaris_ / GTx-758LH inhibitor (oral)1st line metastatic Prostate cancerII
Ostarine_ / enobosarm / GTx-024selective androgen receptor modulator (SARM)Breast cancerII
Ostarine_ / enobosarm / GTx-024selective androgen receptor modulator (SARM)Diffuse large B-cell Lymphoma (DLBCL)IIMerck
Capesaris_ / GTx-758LH inhibitor (oral)2nd line metastatic Prostate cancerI
Gtx-230tubulin inhibitorVarious cancer typesPreclinical
Gtx-186RTK inhibitorVarious cancer typesPreclinical

View additional information on product candidates here »

Pipeline image

Source


http://www.gtxinc.com

Recent News Headlines

GTx Achieves Stage 1 Milestone in Phase 2 Clinical Trial of Enobosarm in ER+/AR+ Breast Cancer

9/8/2016 11:01 am

(StreetInsider) Sept 8, 2016 - Demonstration of Clinical Benefit in a pre-defined number of evaluable patients in Stage 1 of study triggers enrollment for the second and final Stage of study; Stage 1 data expected in Q4 2016; Enobosarm may offer a novel hormonal treatment prior to chemotherapy for women who are ER+/AR+, representing the largest population of breast cancer patients.

Loss of SMAD4 Gene in Certain Colorectal Cancers is Associated With Poor Prognosis

11/6/2015 11:03 am

(AACR) Nov 6, 2015 - Among colorectal cancers, loss of the gene SMAD4 was significantly more common in cancers arising in the hindgut (the left side of the colon to the rectum) than in cancers arising in the midgut (the right side of the colon) and patients with hindgut-derived tumors with SMAD4 loss had worse recurrence-free survival compared with those with hindgut-derived tumors that retained SMAD4.

Pediatric Low-grade Gliomas With CRAF Fusions May Require Differential and Combinatorial Targeted Therapies

11/6/2015 11:03 am

(AACR) Nov 6, 2015 - Unlike pediatric low-grade gliomas (PLGG) that are driven by BRAF fusion proteins, PLGGs that are driven by other forms of RAF fusion proteins, called CRAF fusion proteins, may not respond to single-agent therapy with FDA-approved and investigational RAF inhibitors, suggesting the importance of molecularly stratifying PLGG patients in order to identify appropriate therapies.

Takeda to Present Data from Ixazomib's Phase 3 Study in Relapsed/Refractory Multiple Myeloma at Upcoming American Society of Hematology Annual Meeting

11/6/2015 11:03 am

(Takeda) Nov 5, 2015 - Takeda Pharmaceutical Company Limited today announced that it will present Phase 3 data from the TOURMALINE-MM1 ixazomib clinical trial at the 57th American Society of Hematology (ASH) Annual Meeting to be held in Orlando, Florida from December 5 to 8, 2015.

Seattle Genetics Announces More Than 20 Presentations at ASH 2015 Highlighting Progress with Broad ADCETRIS® (Brentuximab Vedotin) Development Plan and Multiple Antibody-Drug Conjugate (ADC) Pipeline Programs

11/6/2015 11:03 am

(Yahoo! Finance) Nov 6, 2015 - Seattle Genetics, Inc. today announced that a record number of abstracts were accepted for presentation at the 57th American Society of Hematology (ASH) Annual Meeting and Exposition taking place in Orlando, Florida, December 5-8, 2015.

Viralytics and Merck & Co., Inc., Kenilworth, New Jersey, U.S.A. to Collaborate on Combination Clinical Trial of CAVATAK™ and KEYTRUDA® in Lung and Bladder Cancer

11/6/2015 11:03 am

(MarketWatch) Nov 6, 2015 - Viralytics Limited announced today that it has entered into a clinical trial collaboration agreement through subsidiaries of Merck & Co., Inc., Kenilworth, New Jersey, U.S.A. (known as MSD outside the United States and Canada) to evaluate the combination of Viralytics' investigational cancer immunotherapy CAVATAK™, with MSD's KEYTRUDA®, an anti-PD-1 (programmed death receptor-1) therapy.

Gene Editing Credited With Eliminating an Infant's Aggressive Cancer in London

11/6/2015 11:02 am

(Wall Street Journal) Nov 5, 2015 - A novel gene-editing technique has been used to eliminate an infant's aggressive cancer, a small but significant step in the quest to treat deadly diseases by altering the human genome.

The Hottest New Cancer Drugs Depend on Gut Microbes

11/6/2015 11:02 am

(The Atlantic) Nov 5, 2015 - Immunotherapy doesn’t work for everyone, and a series of new studies might explain why.

Why The FDA Rejected A Drug That Cures Lung Cancer -- And What We Can Do To Fix It

11/6/2015 11:02 am

(Forbes) Nov 6, 2015 - Ed Silverman, writing in the Boston Globe October 19th, pointed to lung cancer drug Iressa as a "cautionary tale" against using "surrogate endpoints" – signs that point to, but don't guarantee, a given clinical outcome – for FDA drug approvals.

First Precision Medicine Trial in Cancer Prevention Identifies Molecular-Based Chemoprevention Strategy

11/6/2015 11:02 am

(MD Anderson) Nov 5, 2015 - A team of scientists, led by researchers at The University of Texas MD Anderson Cancer Center and University of California, San Diego Moores Cancer Center, report that a genetic biomarker called loss of heterozygosity or LOH is able to predict which patients with premalignant mouth lesions are at highest risk of developing oral cancer.

TCGA Findings on Papillary Renal Cell Carcinoma and Prostate Cancer

11/6/2015 11:02 am

(NCI News Note) Nov 5, 2015 - Two findings from The Cancer Genome Atlas (TCGA) Research Network were recently published on papillary renal cell carcinoma and prostate cancer.

The Lancet: Adding Ultrasound to Breast Screening Results in Higher Rate of Detection for Women in Japan

11/6/2015 11:02 am

(Science Codex) Nov 5, 2015 - Adding ultrasound to standard mammography tests in breast screening could result in improved rates of detection for breast cancer in women in Japan, according to a new study, published in The Lancet.

Gut Bacteria Can Dramatically Amplify Cancer Immunotherapy

11/6/2015 07:00 am

(University of Chicago Medicine) Nov 5, 2015 - By introducing a particular strain of bacteria into the digestive tracts of mice with melanoma, researchers at the University of Chicago were able to boost the ability of the animal's immune systems to attack tumor cells.

A Cell Therapy Untested in Humans Saves a Baby With Cancer

11/6/2015 07:00 am

(New York Times) Nov 5, 2015 - A baby girl who was close to dying from cancer has been rescued by a cell therapy envisioned as a “one size fits all” treatment that had never been tested in people, doctors reported on Thursday.

Key Data For Amgen Medicines In Relapsed Multiple Myeloma And Acute Lymphoblastic Leukemia To Be Presented At ASH 2015

11/5/2015 12:03 pm

(Amgen) Nov 5, 2015 - Amgen today announced that a number of important abstracts from the Company's oncology portfolio, including Kyprolis® (carfilzomib) for Injection, BLINCYTO® (blinatumomab), Nplate® (romiplostim) and Neulasta® (pegfilgrastim), are scheduled for presentation at the 57th American Society of Hematology (ASH) Annual Meeting and Exposition, Dec. 5–8, 2015, in Orlando, Fla.

New Gene Linked to Lung Cancer Spread and Tumor Formation

11/5/2015 12:03 pm

(Northwestern University) Nov 4, 2015 - Worldwide, lung cancer causes more deaths than any other cancer. Most frequently, mortality is the result of metastasis -- when lung cancer spreads to other parts of the body, such as the brain, bones or liver.

GTx Announces Enrollment of First Patient in Phase 2 Clinical Trial of Enobosarm in Triple Negative Breast Cancer

10/6/2015 10:09 am

(MarketWatch) Oct 6, 2015 - GTx, Inc. today announced the enrollment of the first patient into its Phase 2 clinical trial of enobosarm (GTx-024) to treat women with advanced, androgen receptor positive (AR+), triple negative breast cancer (TNBC).

GTx Announces Enrollment of First Patient in Phase 2 Clinical Trial of Enobosarm in ER+/AR+ Breast Cancer

9/29/2015 11:04 am

(MarketWatch) Sept 29, 2015 - GTx, Inc. today announced the enrollment of the first patient into its Phase 2 clinical trial of enobosarm (GTx-024) to treat women with advanced, estrogen receptor positive (ER+), androgen receptor positive (AR+) breast cancer. Enobosarm, a selective androgen receptor modulator (SARM), is the Company’s lead product candidate.

GTx and the University of Tennessee Research Foundation Enter Into Exclusive License Agreement to Develop UTRF’s SARD Drug Technology

4/23/2015 12:54 pm

(Yahoo! Finance) Apr 23, 2015 - GTx, Inc. today announced that it has entered into an exclusive worldwide license agreement with the University of Tennessee Research Foundation (UTRF) to develop its proprietary selective androgen receptor degrader (SARD) technology which potentially can degrade and inhibit all forms of androgen receptor (AR), including those resistant to current therapies, in patients with progressive castration-resistant prostate cancer (CRPC).

GTx Reports Positive Clinical Data from Open Label Phase 2 Study of Enobosarm in Patients with Androgen and Estrogen Receptor Positive Metastatic Breast Cancer

6/2/2014 06:36 pm

(GTx) June 2, 2014 - GTx, Inc. today announced positive results from a Phase 2, proof-of-concept, open-label clinical study evaluating enobosarm (GTx-024), a selective androgen receptor modulator (SARM), for the treatment of patients with androgen receptor (AR) positive and estrogen receptor (ER) positive metastatic breast cancer who have previously responded to hormonal therapy.

Steiner Resigns From GTx

4/4/2014 12:17 pm

(Memphis Business Journal) Apr 4, 2014 - Mitch Steiner, CEO and co-founder of GTx Inc., has resigned, effective yesterday.

Steiner Resigns From GTx

4/4/2014 12:01 pm

(Memphis Business Journal) Apr 4, 2014 - Mitch Steiner, CEO and co-founder of GTx Inc., has resigned, effective yesterday.

Preliminary Findings From the Phase 2 Clinical Trial of GTx-758 in Men with Castration Resistant Prostate Cancer to Be Presented at ASCO Genitourinary Cancer Symposium

1/29/2014 11:26 am

(GTx) Jan 29, 2014 - GTx, Inc. announced today the presentation of preliminary findings from the Company’s Phase 2 clinical trial evaluating GTx-758 (Capesaris®), an oral estrogen receptor alpha agonist, in men with metastatic castrate resistant prostate cancer (CRPC) at the 2014 ASCO GU Cancer Symposium on Thursday, January 30, 2014.

GTx Announces Late Breaker Presentation on Results from the two Phase 3 POWER Trials of Enobosarm, A Selective Androgen Receptor Modulator (SARM), for the Prevention and Treatment of Muscle Wasting in NSCLC Patients During 2013 European Cancer Congress

9/24/2013 11:31 am

(GTx) Sep 24, 2013 - GTx, Inc. announced today that top line results from the two Phase 3 trials (POWER1 and POWER2) on the effects of enobosarm for the prevention and treatment of muscle wasting in non-small cell lung cancer patients will be presented on September 28, 2013, at the European Cancer Congress 2013 in Amsterdam.

GTx Muscle Drug Fails Late-stage Trials, Shares Plunge

8/19/2013 10:27 am

(Reuters) Aug 19, 2013 - GTx Inc's experimental drug to treat muscle wasting in cancer patients became its second successive lead drug to fail late-stage trials, wiping out nearly two-thirds of the market value of the once-promising cancer-focused pharmaceutical company.

MannKind, Vical, GTx: Investors Predict Pivotal Clinical Trial Results

8/5/2013 11:43 am

(TheStreet) Aug 4, 2013 - A phase III study of Vical's melanoma immunotherapy allovectin-7 will have results ready in August, the company said recently; GTx is conducting two phase III studies of enobosarm in lung-cancer related muscle wasting with data expected to be announced in August.

Biotech Stock Mailbag: GTx, Vanda, Pharmacyclics

7/12/2013 10:13 am

(TheStreet) July 12, 2013 – An analyst defends GTx, and Adam Feuerstein speculates as to ibrutinib’s FDA approval date.

The GTx Cancer Muscle-Wasting Drug Studies Will Fail. Here's Why

7/11/2013 11:40 am

(TheStreet) July 10, 2013 - Before the end of the current quarter, GTx is expected to announce top-line results from two phase III studies of a cancer-related muscle wasting drug known as enobosarm.

GTx Initiating Phase 2, Open-Label Study of Enobosarm to Treat ER Positive Metastatic Breast Cancer

4/30/2013 11:50 am

(GTx) Apr 30, 2013 - GTx, Inc., announced today that it is initiating a proof of concept, Phase 2, open-label clinical study to evaluate enobosarm (GTx-024), a selective androgen receptor modulator (SARM), for the potential treatment of metastatic breast cancer.

GTx's Phase III Clinical Studies of Enobosarm (GTx-024) to Continue as Planned Following Planned Safety Review

4/15/2013 11:13 am

(Yahoo! Finance) Apr 15, 2013 - GTx, Inc. today announced that a per protocol safety review of unblinded safety data by an independent Data Safety Monitoring Board (DSMB), resulted in a determination that GTx continue as planned its two pivotal Phase III clinical trials of enobosarm (GTx-024) for the prevention and treatment of muscle wasting in patients with advanced non-small cell lung cancer.

Novel Findings from Clinical Studies Examining the Effects of Capesaris® (GTx-758) for the Treatment of Advanced Prostate Cancer to be Presented at 2013 American Society of Clinical Oncology Genitourinary Cancer Symposium

2/13/2013 12:14 pm

(Miami Herald) Feb 13, 2013 - GTx, Inc. announced today that new data from two Phase II studies on the effects of Capesaris® (GTx-758), a selective estrogen receptor alpha agonist, for the treatment of advanced prostate cancer, will be detailed in presentations at the ASCO Genitourinary Cancer Symposium in Orlando, Florida.

Novel Findings from Clinical Studies Examining the Effects of Capesaris® (GTx-758) for the Treatment of Advanced Prostate Cancer to be Presented at 2013 American Society of Clinical Oncology Genitourinary Cancer Symposium

2/13/2013 12:01 pm

(Miami Herald) Feb 13, 2013 - GTx, Inc. announced today that new data from two Phase II studies on the effects of Capesaris® (GTx-758), a selective estrogen receptor alpha agonist, for the treatment of advanced prostate cancer, will be detailed in presentations at the ASCO Genitourinary Cancer Symposium in Orlando, Florida.

Comparable Patterns of Failure between SBRT, Lobectomy or Pneumonectomy for Stage I Non-small Cell Lung Cancer

1/15/2013 12:00 pm

(IASLC) Jan 15, 2013 - For patients with medically operable clinical stage I non–small-cell lung cancer (NSCLC), lobectomy or pneumonectomy is the standard approach.

GTx Announces FDA's Grant of Fast Track Designation to Enobosarm For the Prevention and Treatment of Muscle Wasting in Patients with Non-Small Cell Lung Cancer

1/8/2013 12:14 pm

(4-traders) Jan 8, 2013 - GTx, Inc. today announced that the U.S. Food and Drug Administration (FDA) has designated enobosarm (GTx-024) for the prevention and treatment of muscle wasting in patients with non-small cell lung cancer as a Fast Track development program.

GTx Announces FDA's Grant of Fast Track Designation to Enobosarm For the Prevention and Treatment of Muscle Wasting in Patients with Non-Small Cell Lung Cancer

1/8/2013 12:01 pm

(4-traders) Jan 8, 2013 - GTx, Inc. today announced that the U.S. Food and Drug Administration (FDA) has designated enobosarm (GTx-024) for the prevention and treatment of muscle wasting in patients with non-small cell lung cancer as a Fast Track development program.

GTx Attains Enrollment Goal for its Enobosarm POWER 1 and POWER 2 Phase III Clinical Studies

12/17/2012 11:37 am

(Yahoo! Finance) Dec 17, 2012 - GTx, Inc. today announced that it has attained its enrollment goal for both of its pivotal Phase III clinical studies of enobosarm to prevent and treat muscle wasting in non-small cell lung cancer patients.

GTx Attains Enrollment Goal for its Enobosarm POWER 1 and POWER 2 Phase III Clinical Studies

12/17/2012 11:03 am

(Yahoo! Finance) Dec 17, 2012 - GTx, Inc. today announced that it has attained its enrollment goal for both of its pivotal Phase III clinical studies of enobosarm to prevent and treat muscle wasting in non-small cell lung cancer patients.

GTx's Phase III Clinical Development of Enobosarm (GTx-024) for Muscle Wasting in Lung Cancer Patients on Course Following Planned Safety Review

10/29/2012 11:35 am

(Boston.com) Oct 29, 2012 - GTx, Inc. today announced that a per protocol interim safety review on Friday, October 26, 2012, by an independent Data Safety Monitoring Board (DSMB) recommended that GTx continue clinical development as planned with its two pivotal Phase III trials of enobosarm (GTx-024) for the prevention and treatment of muscle wasting in patients with non-small cell lung cancer.

Memphis-based GTx Sells Cancer Drug Fareston for $21.7M

10/1/2012 01:02 pm

(Memphis Commercial Appeal) Oct 1, 2012 - GTx Inc. has sold Fareston, its breast cancer drug, to U.K.-based ProStrakan Group for $21.7 million.

Memphis-based GTx Sells Cancer Drug Fareston for $21.7M

10/1/2012 01:00 pm

(Memphis Commercial Appeal) Oct 1, 2012 - GTx Inc. has sold Fareston, its breast cancer drug, to U.K.-based ProStrakan Group for $21.7 million.

GTx Announces Presentations on the Effect of Enobosarm on Improving Physical Function In Cancer Patients

6/26/2012 11:58 am

(4-Traders) June 26, 2012 - GTx, Inc. announced today there will be two scientific presentations on the effects of enobosarm, a selective androgen receptor modulator (SARM), on improving physical function in cancer patients on June 30, 2012, between 2:30 and 4:00pm eastern daylight time, at the MASCC/ISOO 2012 International Symposium held at the Hilton New York Hotel in New York, New York.

GTx Announces Presentations on the Effect of Enobosarm on Improving Physical Function In Cancer Patients

6/26/2012 11:00 am

[Business Wire] - GTx, Inc. announced today there will be two scientific presentations on the effects of enobosarm, a selective androgen receptor modulator , on improving physic

GTx Announces Presentation on Enobosarm’s Improvement in Physical Function in Cancer Patients with Both Low and Normal Testosterone Levels

6/25/2012 01:00 pm

[Business Wire] - GTx, Inc. announced today that in a Phase IIb clinical study of enobosarm, there was significantly improved physical function after 16 weeks of treatment, compared to placebo, in both hypogonadal and eugonadal subjects.